• Baseline assessment and screening tool for identifying Female Sexual Dysfunction (FSD)
• Measuring therapeutic efficacy of interventions (e.g., localized estrogen, ospemifene, flibanserin)
• Research standard for quantifying multidimensional sexual function in clinical trials

The index consists of 19 questions. Each response is scaled, multiplied by a specific domain factor. The maximum total score is 36. Higher scores equal better function.

• A low score does NOT automatically mean the patient is distressed. By definition, FSD or Hypoactive Sexual Desire Disorder (HSDD) requires the symptoms to cause profound personal distress. If they score a 15 but are perfectly happy, there is no disorder to treat.
• The tool inherently relies on sexual activity within the last 4 weeks. If the patient has been entirely abstinent, the scores artificially zero out.
• It does not diagnose the etiology. It cannot distinguish between SSRI-induced anorgasmia vs. profound marital discord vs. menopausal vaginal atrophy.

• Isolate the driving domain: Look at which of the 6 areas failed the worst.
• Pain/Lubrication Predominant: Suspect Genitourinary Syndrome of Menopause (GSM), vestibulodynia, or endometriosis. Treat first with vaginal moisturizers, escalating to topical vaginal estradiol or DHEA.
• Desire/Arousal Predominant: Evaluate medications (SSRIs/SNRIs, beta blockers), thyroid function, and relationship factors. Consider centrally acting agents (flibanserin/bremelanotide) if premenopausal HSDD is diagnosed.
• Orgasm Predominant: Check SSRI use, pelvic floor dysfunction, or systemic vascular health.

Prior to the year 2000, female sexual function research was remarkably sparse and unstructured compared to men (where the IIEF dominated). Dr. Raymond Rosen and colleagues developed the FSFI to fill this immense void, ultimately standardizing the entire field of female sexual medicine.